What cost-effectiveness demands and market access challenges will novel antibiotics for mdr gnps approved via the streamlined lpad pathway face?
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1414
https://www.valueinhealthjournal.com/article/S1098-3015(15)01471-0/fulltext
Title :
What cost-effectiveness demands and market access challenges will novel antibiotics for mdr gnps approved via the streamlined lpad pathway face?
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01471-0&doi=10.1016/j.jval.2015.03.1414
First page :
A243
Section Title :
Infection
Open access? :
No
Section Order :
880